Literature DB >> 14597628

Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding.

Claus Juul Loland1, Charlotta Grånäs, Jonathan A Javitch, Ulrik Gether.   

Abstract

Recently we showed evidence that mutation of Tyr-335 to Ala (Y335A) in the human dopamine transporter (hDAT) alters the conformational equilibrium of the transport cycle. Here, by substituting, one at a time, 16 different bulky or charged intracellular residues, we identify three residues, Lys-264, Asp-345, and Asp-436, the mutation of which to alanine produces a phenotype similar to that of Y335A. Like Y335A, the mutants (K264A, D345A, and D436A) were characterized by low uptake capacity that was potentiated by Zn(2+). Moreover, the mutants displayed lower affinity for cocaine and other inhibitors, suggesting a role for these residues in maintaining the structural integrity of the inhibitor binding crevice. The conformational state of K264A, Y335A, and D345A was investigated by assessing the accessibility to MTSET ([2-(trimethylammonium)ethyl]-methanethiosulfonate) of a cysteine engineered into position 159 (I159C) in transmembrane segment 3 of the MTSET-insensitive "E2C" background (C90A/C306A). Unlike its effect at the corresponding position in the homologous norepinephrine transporter (NET I155C), MTSET did not inhibit uptake mediated by E2C I159C. Furthermore, no inhibition was observed upon treatment with MTSET in the presence of dopamine, cocaine, or Zn(2+). Without Zn(2+), E2C I159C/K264A, E2C I159C/Y335A, and E2C I159C/D345A were also not inactivated by MTSET. In the presence of Zn(2+) (10 microm), however, MTSET (0.5 mm) caused up to approximately 60% inactivation. As in NET I155C, this inactivation was protected by dopamine and enhanced by cocaine. These data are consistent with a Zn(2+)-dependent partial reversal of a constitutively altered conformational equilibrium in the mutant transporters. They also suggest that the conformational equilibrium produced by the mutations resembles that of the NET more than that of the DAT. Moreover, the data provide evidence that the cocaine-bound state of both DAT mutants and of the NET is structurally distinct from the cocaine-bound state of the DAT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597628     DOI: 10.1074/jbc.M304755200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.

Authors:  Juan Zhen; Solav Ali; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurosci Methods       Date:  2011-09-12       Impact factor: 2.390

Review 2.  Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters.

Authors:  Christopher K Surratt; Okechukwu T Ukairo; Suneetha Ramanujapuram
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

3.  R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse.

Authors:  Claus J Loland; Maddalena Mereu; Oluyomi M Okunola; Jianjing Cao; Thomas E Prisinzano; Sonia Mazier; Theresa Kopajtic; Lei Shi; Jonathan L Katz; Gianluigi Tanda; Amy Hauck Newman
Journal:  Biol Psychiatry       Date:  2012-04-25       Impact factor: 13.382

4.  The mechanism of a neurotransmitter:sodium symporter--inward release of Na+ and substrate is triggered by substrate in a second binding site.

Authors:  Lei Shi; Matthias Quick; Yongfang Zhao; Harel Weinstein; Jonathan A Javitch
Journal:  Mol Cell       Date:  2008-06-20       Impact factor: 17.970

5.  Molecular dynamics of conformation-specific dopamine transporter-inhibitor complexes.

Authors:  Bernandie Jean; Christopher K Surratt; Jeffry D Madura
Journal:  J Mol Graph Model       Date:  2017-07-11       Impact factor: 2.518

6.  An N-terminal threonine mutation produces an efflux-favorable, sodium-primed conformation of the human dopamine transporter.

Authors:  Rheaclare Fraser; Yongyue Chen; Bipasha Guptaroy; Kathryn D Luderman; Stephanie L Stokes; Asim Beg; Louis J DeFelice; Margaret E Gnegy
Journal:  Mol Pharmacol       Date:  2014-04-21       Impact factor: 4.436

7.  Neuropsychiatric disease-associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes.

Authors:  Freja Herborg; Thorvald F Andreassen; Frida Berlin; Claus J Loland; Ulrik Gether
Journal:  J Biol Chem       Date:  2018-03-20       Impact factor: 5.157

8.  The binding sites for cocaine and dopamine in the dopamine transporter overlap.

Authors:  Thijs Beuming; Julie Kniazeff; Marianne L Bergmann; Lei Shi; Luis Gracia; Klaudia Raniszewska; Amy Hauck Newman; Jonathan A Javitch; Harel Weinstein; Ulrik Gether; Claus J Loland
Journal:  Nat Neurosci       Date:  2008-06-22       Impact factor: 24.884

9.  Molecular dynamics simulation studies of GLUT4: substrate-free and substrate-induced dynamics and ATP-mediated glucose transport inhibition.

Authors:  Suma Mohan; Aswathy Sheena; Ninu Poulose; Gopalakrishnapillai Anilkumar
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

10.  Conformational changes in dopamine transporter intracellular regions upon cocaine binding and dopamine translocation.

Authors:  Yvette Dehnes; Jufang Shan; Thijs Beuming; Lei Shi; Harel Weinstein; Jonathan A Javitch
Journal:  Neurochem Int       Date:  2014-02-24       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.